entertainment -WSS

entertainment

author：focus 2025-10-02 11:09:30 - browse：56597

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Medicare Advantage beneficiaries sue Humana over algorithm use

explore

WSS

Study: Spinal cord stimulation helps patients with paralysis walk again

HCA sued by state AG for quality issues at Mission Health

Former Pear Therapeutics executives start new VC firm

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Can U.S. cancer drug shortages be fixed?

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

focus

entertainment

leisure time

How one medical school became remarkably diverse

Vivek Ramaswamy made waves in the debate, much as in biotech

Novavax promises a turnaround & Lilly roils the obesity market

Kellogg’s is going to war over Mexico’s nutrition label rules

Trump demands the U.S. pay no more for drugs than other countries … again

Vivek Ramaswamy made waves in the debate, much as in biotech

Apple is now the first public company to be valued at $3 trillion

As obesity drug market grows, telehealth companies court payers

Jerome Adams on the need for new antivirals for Covid

SEC charges former device maker CEO with $41 million fraud

leisure time

HCA sued by state AG for quality issues at Mission Health

How the drug

Health officials lay out plans to cope with respiratory virus season

Virtual care provider acquires bankrupt Pear's prescription apps

Medicare drug price negotiation hasn't dried up venture capital

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

hotspot

explore

leisure time

leisure time